Focused first indication
Liver cancer patients whose liver reserve is too poor to tolerate potentially curative surgery.
Restore liver function.Unlock the opportunity.
REGEN001 is designed to restore liver function, and so to widen the treatment options open to patients. A focused RNA programme, built to generate evidence and partner from strength.
Request the investor brief
THE INVESTMENT THESIS
A defined need.
A disciplined ambition.
REGEN001 begins with a focused surgical setting and an established RNA therapeutic foundation. Apterna’s strategy connects early biological validation with a broader potential application across liver disease.
The company aims to progress key proof-of-concept milestones, then work with strategic partners for further development, scale, and reach.
FOUR PILLARS
Clarity at every stage.
Established modality
A GalNAc-siRNA foundation applied to a new liver functional restoration opportunity.
Broader liver horizons
Potential future relevance across cirrhosis, transplant avoidance, and metabolic liver disease.
Built to partner
A development model structured around proof of concept and strategic collaboration.
POTENTIAL COMBINATION STRATEGY
Complementing GLP-1 therapy.
GLP-1 receptor agonists address metabolic pathways. REGEN001 targets hepatic C/EBP-beta, with the aim of improving liver function. These different mechanisms provide a rationale to study a complementary approach alongside GLP-1 therapy.
The potential value is added liver-function benefit. Combination efficacy, safety and tolerability remain to be demonstrated: the published REGEN001 study did not test GLP-1 co-administration or show reduced GLP-1 side effects. REGEN001 remains preclinical.
Semaglutide has a US indication for noncirrhotic MASH with F2-F3 fibrosis, establishing a relevant standard against which added benefit would need to be tested. Read the published mouse study and the FDA announcement.
DEVELOPMENT & VALUE CREATION
Evidence builds the opportunity.
PLANNED · 2026
Lead selection
Optimisation and in vitro proof of concept to test the intended biological effect.
Company development plan. Timelines are prospective and depend on funding, study outcomes, and regulatory review.
NARRATED BRIEFING
Watch the briefingThe programme in three minutes.
REGEN001 in plain English — the patient, the market, the team. It plays in the browser, with no sign-in and nothing to download.
INVESTOR MATERIALS
The decks and the documents.
Narrated decks, programme documents and a confidential investor pack, with narrated editions in Arabic, Persian and Hindi. Two are open to everyone; the rest ask you to sign in.
View the materialsCONFIDENTIAL INVESTOR PACK
- Financial opportunity17 slides
- Financing modelXLSX
- Investor Q&A6 pages
- Management questions4 pages
NARRATED DECKS
- The three-minute briefing2½ minOpen to all
- The short scientific deck13 min
- The full scientific deck19 min
DOCUMENTS
- One-page summary1 page
- Investor deck10 pages
- Programme overview10 pagesOpen to all
COMPANY-PUBLISHED MATERIAL
View scenariosExplore the illustrative scenarios.
A separate overview of the assumptions and risks in Apterna’s published investment scenarios.
THE PEOPLE WHO BUILD
Clinical depth.
Development experience.
A founding team connecting liver surgery, global drug development and biotechnology operations.
YOUR QUESTIONS, ADDRESSED
A clearer view of the opportunity.
What is the first clinical opportunity?
REGEN001 is being developed for liver cancer patients whose poor liver reserve limits access to potentially curative surgery. The aim is to restore function sufficiently to broaden treatment options. This remains an investigational, preclinical programme.
What would the next phase of funding advance?
The development plan prioritises lead optimisation, biological proof of concept and disease-relevant validation. Subsequent toxicology, manufacturing and regulatory preparation depend on the evidence and the programme’s decision gates. Discuss the current financing plan directly with the team.
How does Apterna intend to create value?
The strategy is to generate a coherent proof-of-concept package around a defined clinical need, then pursue strategic collaboration for further development and scale. Broader liver indications represent future research opportunities rather than established outcomes.
Which materials can investors request?
Request the corporate overview or arrange a discussion of programme milestones, development assumptions and the current investment case. The March 2026 scenario analysis is illustrative and is not a guarantee of returns.
Request an investor discussionSTART A DISCUSSION
Meet the people behind the programme.
We welcome introductions from specialist investors, venture partners, and corporate development teams.
Request investor materialsFor co-development, platform licensing, and strategic partnerships, connect with our team.
Discuss a partnershipThis page is company information, not an offer to sell securities. Development involves scientific, regulatory, and financial uncertainty.
CONTINUE EXPLORING
